Cargando…

Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells

Multidrug resistance (MDR) triggered by ATP binding cassette (ABC) transporter such as ABCB1, ABCC1, ABCG2 limited successful cancer chemotherapy. Unfortunately, no commercial available MDR modulator approved by FDA was used in clinic. Tyrosine kinase inhibitors (TKIs) have been administrated to fig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Shaocong, Fu, Liwu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817862/ https://www.ncbi.nlm.nih.gov/pubmed/29455646 http://dx.doi.org/10.1186/s12943-018-0775-3

Ejemplares similares

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Branebrutinib (BMS-986195), a Bruton’s Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents
por: Wu, Chung-Pu, et al.
Publicado: (2021)

Reversing multidrug resistance by tyrosine kinase inhibitors
por: He, Miao, et al.
Publicado: (2012)

Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo
por: Guo, Xiaoran, et al.
Publicado: (2018)

Rociletinib (CO-1686) enhanced the efficacy of chemotherapeutic agents in ABCG2-overexpressing cancer cells in vitro and in vivo
por: Zeng, Fanpu, et al.
Publicado: (2020)

Cetuximab enhanced the efficacy of chemotherapeutic agent in ABCB1/P-glycoprotein-overexpressing cancer cells
por: Wang, Fang, et al.
Publicado: (2015)

Incorporation of drug efflux inhibitor and chemotherapeutic agent into an inorganic/organic platform for the effective treatment of multidrug resistant breast cancer
por: Dong, Yang, et al.
Publicado: (2019)

Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, in vivo, and ex vivo
por: Fan, Yingfang, et al.
Publicado: (2022)

BIRB796, the Inhibitor of p38 Mitogen-Activated Protein Kinase, Enhances the Efficacy of Chemotherapeutic Agents in ABCB1 Overexpression Cells
por: He, Dan, et al.
Publicado: (2013)

PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
por: Luo, Min, et al.
Publicado: (2021)

NOTCH1 inhibition enhances the efficacy of conventional chemotherapeutic agents by targeting head neck cancer stem cell
por: Zhao, Zhi-Li, et al.
Publicado: (2016)

STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell
por: Bu, Lin-Lin, et al.
Publicado: (2015)

Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration
por: Krchniakova, Maria, et al.
Publicado: (2020)

Hyperthermia Enhances Efficacy of Chemotherapeutic Agents in Pancreatic Cancer Cell Lines
por: Maurici, Costanza E., et al.
Publicado: (2022)

Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes
por: Dai, ChunLing, et al.
Publicado: (2015)

Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance
por: Anreddy, Nagaraju, et al.
Publicado: (2014)

Involvement of P-gp on Reversing Multidrug Resistance Effects of 23-Hydroxybetulinic Acid on Chemotherapeutic Agents
por: Liu, Zhihao, et al.
Publicado: (2021)

Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer
por: Luo, Min, et al.
Publicado: (2020)

CM082 Enhances the Efficacy of Chemotherapeutic Drugs by Inhibiting the Drug Efflux Function of ABCG2
por: Xu, Lejia, et al.
Publicado: (2019)

CM082 Enhances the Efficacy of Chemotherapeutic Drugs by Inhibiting the Drug Efflux Function of ABCG2
por: Xu, Lejia, et al.
Publicado: (2023)

Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo
por: Hu, Jing, et al.
Publicado: (2015)

Linifanib (ABT-869) Potentiates the Efficacy of Chemotherapeutic Agents through the Suppression of Receptor Tyrosine Kinase-Mediated AKT/mTOR Signaling Pathways in Gastric Cancer
por: Chen, Jing, et al.
Publicado: (2016)

Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells
por: Ogata, Ryohei, et al.
Publicado: (2020)

Nobiletin enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cancer cells
por: Ma, Wenzhe, et al.
Publicado: (2015)

Bruton’s Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells
por: Dong, Xing-Duo, et al.
Publicado: (2020)

Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells
por: Nanayakkara, Amila K., et al.
Publicado: (2018)

Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells
por: Elbezanti, Weam Othman, et al.
Publicado: (2022)

Chemotherapeutic efficacy of the protein-doxorubicin conjugates on multidrug resistant rat hepatoma cell line in vitro.
por: Ohkawa, K., et al.
Publicado: (1993)

Synergistic Effects of Plant Derivatives and Conventional Chemotherapeutic Agents: An Update on the Cancer Perspective
por: Pezzani, Raffaele, et al.
Publicado: (2019)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
por: Yao, Yu, et al.
Publicado: (2023)

Analysis of the Efficacy of Multidrug Combination Chemotherapy Regimens for Osteosarcoma and the Management of Chemotherapeutic Reactions
por: Tian, Dawei, et al.
Publicado: (2022)

Knockdown of the Inhibitor of Apoptosis BRUCE Sensitizes Resistant Breast Cancer Cells to Chemotherapeutic Agents
por: Garrison, Jason B, et al.
Publicado: (2015)

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
por: Holt, S V, et al.
Publicado: (2012)

New Therapeutic Strategy for Overcoming Multidrug Resistance in Cancer Cells with Pyrazolo[3,4-d]pyrimidine Tyrosine Kinase Inhibitors
por: Podolski-Renić, Ana, et al.
Publicado: (2021)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Resveratrol enhances the sensitivity of cholangiocarcinoma to chemotherapeutic agents
por: Frampton, Gabriel, et al.
Publicado: (2010)

Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care
por: Gillooly, Kathleen M., et al.
Publicado: (2017)

The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance
por: Narayanan, Silpa, et al.
Publicado: (2021)

P1603: EFFICACY AND SAFETY OF BRUTON’S TYROSINE KINASE INHIBITOR ZANUBRUTINIB IN ITP
por: Huang, Qiu-Sha, et al.
Publicado: (2023)

PB1771: OVERCOMING RESISTANCE TO TYROSINE KINASE INHIBITORS IN MYELOID LEUKEMIA CELLS THROUGH ENHANCED FERROPTOSIS
por: Chien, Chih-Fang Chang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9ngs13fi945bkcfp2enslganbi